Sana Biotechnology Announces Publication in Nature Biotechnology of in . . . Sana Biotechnology, Inc is focused on creating and delivering engineered cells as medicines for patients We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients
Sana Biotechnology Reports Third Quarter 2025 Financial Results and . . . SEATTLE, Nov 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the third quarter 2025
Sana Biotechnology Appoints Brian Piper as Executive Vice President . . . Sana Biotechnology, Inc is focused on creating and delivering engineered cells as medicines for patients We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients
Sana Biotechnology to Present at the 44th Annual J. P. Morgan Healthcare . . . Sana Biotechnology, Inc is focused on creating and delivering engineered cells as medicines for patients We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients
Home - Sana Biotechnology Sana is creating engineered cells to repair and control genes in cells or replace missing or damaged cells to solve the underlying causes of disease
Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial . . . SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2024
For Patients - Sana Biotechnology Sana is a science-driven, patient-centric company filled with employees who wake up everyday focused on advancing potentially curative medicines for people in need
Calendario